Aim: To study the course of pregnancy and childbirth in women with epilepsy, to clarify the effect of immunomodulating therapy with interferon-α2b on the immunological reactivity in pregnant women with epilepsy and the condition of newborns. Materials and methods. 129 pregnant women with epilepsy were examined. After the examination of the neuroimmune status — serum levels of antibodies to neurospecific proteins in the second trimester of pregnancy — the patients were divided into 3 groups. Group 1 included 59 pregnant women with idiopathic epilepsy who had a reduced level of neuroantibodies. The second group included 42 pregnant women with idiopathic epilepsy, in whom an increased level of antibodies to neurospecific proteins was detected (polyneurosensitization). In addition to standard therapy, these patients received interferon α-2b treatment. The third group, the comparison group, included 28 pregnant women with epilepsy with neurosensitization within the reference values, which at the time of pregnancy did not receive antiepileptic therapy and had no convulsive attacks for more than 3 years. Standard clinical laboratory, ultrasound, morphological methods and neuroimmunological studies were conducted. Results. The course of pregnancy was complicated in all pregnant women of the 1st and 2nd groups (early toxicosis, threatening abortion, threatened premature labor, fetoplacental insufficiency, fetal growth retardation). Full-term delivery occurred in 98% of patients, spontaneous delivery — in 82.9% of the patients, cesarean section was performed in 17.1%. A complicated course of labor was registered in 1% of women in labor. There were no seizures during childbirth and in the postpartum period in nursing puerperas (98.5%). In the 2nd group of patients with a high level of sensitization to a wide range of neurospecific proteins, a statistically significant decrease in the content of interferon-α and γ was noted. Sensitization to neurospecific proteins in patients of the 2nd group after treatment with interferon-α2b improved significantly. In newborns of the 2nd group, the levels of neurospecific proteins were within the reference values. There were no clinical manifestations of severe forms of intrauterine infection in newborns of the 2nd group. Conclusion. It has been established that antenatal immunocorrection carried out from the second trimester of pregnancy plays a significant role in preventing the development of neurosensitization and severe forms of intrauterine infection in newborns born to mothers with epilepsy and polyneurosensitization.